Ara-290 dosage chart

16 mg Vial

Ara-290 is dosed at 2 mg–4 mg daily via subcutaneous injection in educational protocols. A 16 mg vial reconstituted with bacteriostatic water yields about 8 mg/mL. This information is for research and educational use only.

Reconstitute: Add 2.0 mL bacteriostatic water → 8 mg/mL concentration.
Target dose: 4 mg once daily subcutaneously (after initial 2 mg titration).
Easy measuring: At 8 mg/mL, 1 unit = 0.01 mL = 80 mcg on a U-100 insulin syringe.
Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); reconstituted: refrigerate and use within 28 days.
Injection frequency: Once daily — 5 days on, 2 days off (dose Mon–Fri, rest Sat–Sun).
Dosing schedule: 5 days on / 2 days off: dose Monday through Friday, then take Saturday and Sunday off. That is 5 dosing days per week.

Dosing schedule

Week	Daily Dose	Units (per injection) (mL)
Week 1	2 mg (2,000 mcg)	25 units (0.25 mL)
Weeks 2–8 (or up to 16)	4 mg (4,000 mcg)	50 units (0.50 mL)

Reconstitution steps

1Draw 2.0 mL bacteriostatic water with a sterile syringe.
2Inject slowly down the vial wall; avoid foaming.
3Gently swirl or roll until fully dissolved (do not shake vigorously).
4Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Dosing Cycle & Timing

This protocol runs on a 5 days on / 2 days off cycle.

Cycle: 5 days on, 2 days off — dose Monday through Friday and rest on the weekend.
5 dosing days per week; the 2 off days help limit receptor desensitisation and give injection sites time to recover.
Keep the dose time consistent on dosing days.
If a weekday dose is missed, take it the same day if possible — do not dose on an off day to catch up.
Weekly totals in the supplies and shopping lists are calculated on 5 dosing days, not 7.

Important Notes

Practical considerations for consistency and safety.

Use a new sterile insulin syringe for each injection; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy.
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily dose and injection site to maintain consistency.
No clinically significant adverse effects were reported at 4 mg/day in 28-day clinical trials.

How This Works

Ara-290 (cibinetide) binds to the innate repair receptor (IRR), a heterodimer of EPOR and CD131 (βc subunit), which is distinct from the classical erythropoietin receptor. This selective binding triggers anti-apoptotic and anti-inflammatory signaling cascades that protect tissues and promote repair without stimulating erythropoiesis. Preclinical research demonstrates that Ara-290 can reprogram a pro-inflammatory, tissue-damaging environment into one favoring healing and regeneration. Additionally, analgesic effects have been observed through immunomodulation and direct inhibition of TRPV1 ion channels activated by capsaicin.

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

Neuroprotection: Clinical trials in diabetic neuropathy showed improvements in HbA1c, lipid profiles, and neuropathic pain scores with 4 mg daily dosing.
Nerve regeneration: In sarcoidosis-associated small-fiber neuropathy, treatment led to significant increases in corneal nerve fiber density (objective nerve regrowth) and improved symptoms compared to placebo.
Tissue protection: Anti-inflammatory and anti-apoptotic effects observed across multiple organ systems in preclinical models.
No erythropoietic effects: Unlike full EPO, Ara-290 does not stimulate red blood cell production, avoiding related side effects.
Tolerability: Well tolerated in clinical studies; occasional mild injection-site reactions (redness, transient discomfort) may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies that may support therapeutic goals.

Optimize glycemic control through diet and medication adherence if addressing diabetic neuropathy.
Incorporate regular physical activity appropriate to individual capacity to support nerve health and circulation.
Prioritize adequate sleep and stress management to support tissue repair processes.
Avoid smoking and limit alcohol consumption, both of which can exacerbate neuropathic conditions.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

Clean the vial stopper and injection site with alcohol swabs; allow to dry completely.
Select a fatty subcutaneous site: lower abdomen (at least 2 inches from navel), outer thigh, or back of upper arm.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
Aspiration is not required for subcutaneous injections; inject slowly and steadily.
Rotate sites systematically with each dose to avoid lipohypertrophy and local tissue changes.
After injection, withdraw the needle and apply gentle pressure with clean gauze; do not rub the site.

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

Supplies needed

Plan covers the full 8-week protocol at the lowest listed starting dose: 2 mg per dose, 5 days on / 2 days off (40 administrations in total), using 16 mg vials. After mixing with 2 mL, the concentration is 8 mg/mL and each dose requires 0.25 mL total.

Ara-290 vials (16 mg each)

Vials are rounded up only after calculating the whole protocol: ceil(80 ÷ 16) = 5. Usable peptide remaining in an opened vial carries forward to the next dose.

Full protocol (8 weeks): 5 vials (80 mg needed ÷ 16 mg)

Insulin syringes (U-100, 1 mL)

One fresh syringe per administration.

Full protocol (8 weeks): 40 syringes

Bacteriostatic water (10 mL bottles)

Use 2 mL per vial for reconstitution (5 × 2 mL = 10 mL).

Full protocol (8 weeks): 1 × 10 mL bottle

Alcohol swabs

One for the vial stopper per draw + one for each injection site (5 days on / 2 days off). Recommend 1 × 100-count box.

Full protocol (8 weeks): 80 swabs

Supply	Full protocol (8 weeks)
Ara-290 vials (16 mg each)Vials are rounded up only after calculating the whole protocol: ceil(80 ÷ 16) = 5. Usable peptide remaining in an opened vial carries forward to the next dose.	5 vials (80 mg needed ÷ 16 mg)
Insulin syringes (U-100, 1 mL)One fresh syringe per administration.	40 syringes
Bacteriostatic water (10 mL bottles)Use 2 mL per vial for reconstitution (5 × 2 mL = 10 mL).	1 × 10 mL bottle
Alcohol swabsOne for the vial stopper per draw + one for each injection site (5 days on / 2 days off). Recommend 1 × 100-count box.	80 swabs

Ara-290 dosage FAQs

How much bacteriostatic water do you use to reconstitute Ara-290?

Add 2.0 mL bacteriostatic water → 8 mg/mL concentration. for a 16 mg Vial vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.

What is a typical Ara-290 dose?

Target dose: 4 mg once daily subcutaneously (after initial 2 mg titration).. Figures are research reference values only.

How often is Ara-290 administered in research protocols?

Injection frequency: Once daily — 5 days on, 2 days off (dose Mon–Fri, rest Sat–Sun).

What does the Ara-290 dosing schedule look like?

Week 1 — 2 mg (2,000 mcg) — 25 units (0.25 mL); Weeks 2–8 (or up to 16) — 4 mg (4,000 mcg) — 50 units (0.50 mL). The full table above lists every step with matching syringe units.

What are the mixing steps for Ara-290?

Draw 2.0 mL bacteriostatic water with a sterile syringe. Inject slowly down the vial wall; avoid foaming. Gently swirl or roll until fully dissolved (do not shake vigorously).

How should reconstituted Ara-290 be stored?

Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); reconstituted: refrigerate and use within 28 days..

How many insulin syringe units equal a Ara-290 dose?

Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.

Is Ara-290 approved for human use?

No. Ara-290 is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.

Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.

On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.